FDMT 4D Molecular Therapeutics

4DMT to Participate in Upcoming Investor Conferences

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings.

Leerink's Global Biopharma Conference 2025

Presentation Date: Tuesday, March 11, 2025

Presentation Time: 10:00 a.m. ET

Webcast Link: 

Barclays Global Healthcare Conference 2025

Presentation Date: Wednesday, March 12, 2025

Presentation Time: 10:00 a.m. ET

Webcast Link: 

Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at .

About 4DMT

4DMT is a late-stage biotechnology company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of directed evolution with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our lead program 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, safe, intravitreal injection. Our second core program is 4D-710, which is the first known genetic medicine to demonstrate, in the lungs of people with cystic fibrosis (CF), successful delivery and expression of the CFTR transgene and initial clinical activity signals after aerosol delivery of a gene therapy. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.

Learn more at and follow us on .

Contacts:

Media:

Jenn Gordon

dna Communications

Investors:

Julian Pei

Head of Investor Relations and Corporate Finance



EN
19/02/2025

Underlying

FDMT4D Molecular Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 4D Molecular Therapeutics

 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT Reports Full Year 2024 Financial Results, Operational Highlights ...

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and continued favorable tolerability     Announced positive interim 32-week data for 4D-150 in DME from Part 1 of SPECTRA clinical trial and alignment with FDA for a single Phase 3 trial being acceptable for the basis of BLA submission for 4D-150 in DME when combined with data generated fro...

6h / 32m 1 EN
 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT to Participate in Upcoming Investor Conferences

4DMT to Participate in Upcoming Investor Conferences EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings. Leerink's Global Biopharma Conference 2025 Presentation Date: Tuesday, March 11, 2025Presentation Time: 10:0...

February 19, 2025 1 EN
 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM W...

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program 3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeksIn the recently diagnosed subgroup, which most resembles the Phase 3 4FRONT-1 and 4FRONT-2 patient populations, 87% required 0-1 supplemental injection and 80% were injection-free through 52 weeksDurable and stable aflibercept expression demon...

February 8, 2025 1 EN
 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT Announces Corporate Webcast to Review Interim 52-week Results fro...

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal Investigator in PRISM, at Angiogenesis, Exudation, and Degeneration 2025 on Saturday, February 8, 2025 at 2:20 p.m. ETCompany to host webcast on Monday, February 10, 2025 at 8:00 a.m. ET to discuss the 4D-150 interim data including recently diagnosed subgroup, which most resembles the Phase 3 4FRONT-1 and -2 pati...

January 29, 2025 1 EN
 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710...

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosisAfter alignment with FDA and EMA on trial designs for the 4D-150 Phase 3 4FRONT program in wet AMD, 4FRONT-1 and 4FRONT-2 trials on track to initiate in Q1 2025 and Q3 2025 respectivelyPrimary endpoint 52-week topline data for both 4FRONT-1 and 4FRONT-2 expected in H2 2027Cash runway extended under u...

January 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch